-
Cancer Jun 1981Seventeen patients with cancer or aplastic anemia received demeclocycline as treatment for hyponatremia. Prior to demeclocycline therapy no patients showed clinical...
Seventeen patients with cancer or aplastic anemia received demeclocycline as treatment for hyponatremia. Prior to demeclocycline therapy no patients showed clinical signs of fluid overload or saline depletion. In all patients inappropriately concentrated urine (mean urine osmolality = 548 mOSM/kg H2O) or increased urine content of sodium (mean urine sodium = 91 mEq/L) were documented prior to demeclocycline therapy. No patient had developed hyponatremia in association with antineoplastic drug therapy. The average serum sodium (NaS) at the time of initiation of therapy was 121 mEq/L. NaS increased in all patients despite the simultaneous administration of generous volumes of fluid. NaS exceeded 130 mEq/L and average of 3.5 days following institution of demeclocycline. Patients lost an average of 2.3 kg during demeclocycline. The toxicity noted following demeclocycline was azotemia and increased serum creatinine. Eight patients developed serum urea nitrogen (SUN) in excess of 25 mg/dl; average maximum creatinine in these eight patients was 1.9 mg/dl. Average peak creatinine in eight patients who did not develop azotemia was 0.87 mg/dl. Azotemia seemed to be correlated with simultaneous administration of other nephrotoxic agents and with administration of higher doses (1200 mg/day) of demeclocycline.
Topics: Creatinine; Demeclocycline; Humans; Hyponatremia; Neoplasms; Osmolar Concentration; Uremia; Water Intoxication
PubMed: 6790160
DOI: 10.1002/1097-0142(19810615)47:12<2908::aid-cncr2820471228>3.0.co;2-r -
Annals of Internal Medicine Aug 1977Three patients with cirrhosis, ascites, and dilutional hyponatremia were treated with demeclocycline in an attempt to correct the abnormal water retention....
Three patients with cirrhosis, ascites, and dilutional hyponatremia were treated with demeclocycline in an attempt to correct the abnormal water retention. Demeclocycline administration (600 to 900 mg/day for 8 to 9 days) resulted in [a] increased blood urea nitrogen and plasma creatinine concentrations; [b] reduction of the inulin clearance by between 63% to 78% and of paraaminophippurate clearance by 36% to 77%; and [c] an impairment of the renal concentrating ability. Urine osmolality decreased to hypotonic levels, but polyuria did not appear, probably because it was prevented by the reduction of the glomerular filtration rate. Renal failure was reversible on withdrawal of demeclocycline. No other causes than demeclocycline administration could be found to explain the reduction of the glomerular filtration rate and the estimated renal plasma flow.
Topics: Blood Urea Nitrogen; Demeclocycline; Glomerular Filtration Rate; Kidney; Kidney Diseases; Kidney Tubules; Liver Cirrhosis; Regional Blood Flow
PubMed: 407825
DOI: 10.7326/0003-4819-87-2-195 -
British Dental Journal May 1996
Topics: Anti-Bacterial Agents; Demeclocycline; Drug Combinations; Drug Stability; Time Factors; Triamcinolone Acetonide
PubMed: 8652295
DOI: 10.1038/sj.bdj.4809088 -
The Journal of Investigative Dermatology Mar 1974
Review
Topics: Acne Vulgaris; Clindamycin; Demeclocycline; Fatty Acids; Fatty Acids, Nonesterified; Humans; Neomycin; Propionibacterium acnes; Sebum; Staphylococcus; Triglycerides
PubMed: 4274211
DOI: 10.1111/1523-1747.ep12724289 -
Archives of Dermatology Jul 1972
Topics: Acne Vulgaris; Adolescent; Adult; Demeclocycline; Dermatitis; Drug Hypersensitivity; Female; Humans; Male; Photosensitivity Disorders; Skin; Sunburn; Time Factors
PubMed: 4261050
DOI: No ID Found -
Australian Endodontic Journal : the... Dec 2012Discolouration of teeth following application of intra-canal antibiotic pastes is a clinical concern. This laboratory study compared the extent of tooth discolouration...
Discolouration of teeth following application of intra-canal antibiotic pastes is a clinical concern. This laboratory study compared the extent of tooth discolouration from three antibiotic pastes over 4 weeks. A total of 120 root samples were prepared and the canals filled with either Ledermix (demeclocyline), Odontopaste (clindamycin) or DoxyPaste (doxycycline). Roots were photographed before and 2 or 4 weeks after incubation at 37°C and 100% humidity in complete darkness in opaque containers. Digital images were standardised and assessed for changes in luminosity. Ledermix paste caused the most discolouration of the three, at both 2 and 4 weeks. There was no significant difference between DoxyPaste and Odontopaste at 2 weeks, whereas at 4 weeks, DoxyPaste caused a greater decrease in luminosity (P < 0.05), darkening more over the second 2-week interval than treatment with Odontopaste (P < 0.05). Under zero light conditions, staining with Ledermix can still occur; indicating non-light-based chemical reactions in the staining process. Doxycycline containing intra-canal medicaments caused less staining despite being a tetracycline-based medicament.
Topics: Anti-Bacterial Agents; Clindamycin; Demeclocycline; Doxycycline; Humans; Light; Tooth Discoloration; Tooth Root
PubMed: 23211072
DOI: 10.1111/aej.12000 -
British Medical Journal May 1978
Topics: Demeclocycline; Diuresis; Heart Failure; Humans; Osmolar Concentration; Sodium
PubMed: 417752
DOI: 10.1136/bmj.1.6122.1282-a -
British Journal of Clinical Pharmacology Jun 1984The anti-diuretic action of carbamazepine, before and after concurrent treatment with demeclocycline, has been studied in a single epileptic subject, in whom two...
The anti-diuretic action of carbamazepine, before and after concurrent treatment with demeclocycline, has been studied in a single epileptic subject, in whom two episodes of status epilepticus had been associated with excessive fluid intake and hyponatraemia. After addition of demeclocyline, free water clearance, plasma arginine vasopressin concentration and serum osmolality (all appreciably reduced after carbamazepine alone) increased but did not revert to normal. The findings are consistent with direct antagonism by demeclocycline of the enhancing effect of carbamazepine on endogenous ADH activity.
Topics: Adult; Carbamazepine; Demeclocycline; Female; Humans; Vasopressins; Water Intoxication
PubMed: 6430315
DOI: 10.1111/j.1365-2125.1984.tb02415.x -
The New England Journal of Medicine Jan 1978We evaluated demeclocycline and lithium therapy in 10 patients with the syndrome of inappropriate secretion of antidiuretic hormone. Despite severe water restriction,... (Comparative Study)
Comparative Study
We evaluated demeclocycline and lithium therapy in 10 patients with the syndrome of inappropriate secretion of antidiuretic hormone. Despite severe water restriction, all patients had hyponatremia (mean +/- S.E.M. serum sodium of 122 +/- 1.1 meq per liter) and elevated urine osmolality (744 +/- 59 mOsm per kilogram) before treatment. Demeclocycline (600 to 1200 mg daily) restored serum sodium concentration to 139 +/- 1.1 meq per liter within five to 14 days, permitting unrestricted water intake in all patients. In three patients given lithium carbonate (900 mg daily) the serum sodium concentration, urine osmolality and urine volume were unchanged; since two patients had adverse central-nervous-system symptoms during lithium therapy, further study of this agent was abandoned. A patient with an unusual 22-year history of the syndrome was unresponsive to lithium, whereas long-term treatment with demeclocyline was markedly effective. Demeclocycline is superior to lithium in the treatment of the syndrome and may obviate the need for severe water restriction.
Topics: Adult; Aged; Child; Chronic Disease; Demeclocycline; Drug Evaluation; Female; Humans; Hyponatremia; Lithium; Male; Middle Aged; Osmolar Concentration; Sodium; Syndrome; Vasopressins
PubMed: 413037
DOI: 10.1056/NEJM197801262980401 -
The American Surgeon Mar 1998The purpose of this study was to evaluate the perioperative effects of demeclocycline on vasopressin (VP) in patients undergoing surgery, specifically coronary artery... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
The purpose of this study was to evaluate the perioperative effects of demeclocycline on vasopressin (VP) in patients undergoing surgery, specifically coronary artery bypass grafting (CABG). This was a prospective, double-blind placebo-controlled clinical study using human subjects in a 575-bed tertiary care teaching community hospital. Thirty patients (20 males and 10 females) undergoing elective CABG over a 6-month period were randomized preoperatively to receive either demeclocycline or a placebo. Each patient received either a total of 1200 mg daily of demeclocycline or a placebo beginning 5 days preoperatively and continuing through postoperative day 2. Urine and serum osmolality, electrolytes, and VP levels were measured daily. Perioperative VP levels were significantly higher (P = 0.05) in the demeclocycline group despite decreased VP activity. The postoperative serum sodium and osmolality remained normal in the demeclocycline group and significantly decreased in the placebo group (P < 0.01). The urine osmolality increased significantly in the placebo group (P = 0.04) on postoperative day 1. We conclude that perioperative administration of demeclocycline reliably inhibits the effects of increased VP secretion commonly seen in patients undergoing CABG procedures. Applying these findings to surgical patients who are at increased risk of complicated fluid and electrolyte problems requires further study.
Topics: Adult; Aged; Anti-Bacterial Agents; Coronary Artery Bypass; Demeclocycline; Double-Blind Method; Female; Humans; Male; Middle Aged; Osmolar Concentration; Perioperative Care; Prospective Studies; Sodium; Vasopressins
PubMed: 9520826
DOI: No ID Found